Group 1 - The core viewpoint of the news is that Guoyao Yicai's subsidiary, Guoyao Holdings Guangxi Co., has received approval for the environmental assessment of its radioactive drug storage project, with a total investment of 995,000 yuan [1] - The "A-share Green Report" project aims to enhance the transparency of environmental information for listed companies, utilizing authoritative environmental regulatory data from 31 provinces and 337 cities [1] - The latest A-share Green Weekly Report indicated that six listed companies have recently exposed environmental risks [1]

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.19% on January 15, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index closed at 14306.73, up 0.41% [1] Individual Stock Performance - Notable gainers included: - RunDa Medical (603108) with a closing price of 20.04, up 1.83% and a trading volume of 700,800 shares [1] - LiuYao Group (603368) closed at 18.58, up 0.60% with a trading volume of 79,700 shares [1] - LaoBaiXing (603883) closed at 16.11, up 0.50% with a trading volume of 226,200 shares [1] - Significant decliners included: - Huaren Health (301408) closed at 23.81, down 19.99% with a trading volume of 491,100 shares [2] - ShangYu PingMin (301017) closed at 18.50, down 13.75% with a trading volume of 373,900 shares [2] - YaoYiGou (300937) closed at 37.40, down 11.79% with a trading volume of 121,400 shares [2] Capital Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 990 million yuan from institutional investors, while retail investors had a net inflow of 977 million yuan [2] - The table of capital flow indicates that: - LaoBaiXing (603883) had a net inflow of 46.10 million yuan from institutional investors [3] - JiuZhouTong (600998) had a net inflow of 40.43 million yuan from institutional investors [3] - RunDa Medical (603108) had a net inflow of 37.80 million yuan from institutional investors [3]

证券日报网讯 1月14日，国药一致在互动平台回答投资者提问时表示，公司会根据经营需要，探索设备 技术革新，合理降低物流成本。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 1月14日，国药一致在互动平台回答投资者提问时表示，公司将根据业务发展需求，积极 引入先进生产力要素，优化物流环节，实现降本增效。 ...

Market Performance - The pharmaceutical commercial sector increased by 0.97% compared to the previous trading day, with Luyuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Key stocks in the pharmaceutical commercial sector showed significant gains, with Yinghe Pharmaceutical rising by 10.02% to a closing price of 22.72, and Jiashitang also increasing by 10.00% to 17.38 [1] - Other notable performers included Saili Medical and Renmin Tongtai, both showing increases of 10.00% and 2.64% respectively [1] Trading Volume and Value - Yinghe Pharmaceutical had a trading volume of 636,200 shares, resulting in a transaction value of approximately 1.396 billion yuan [1] - Jiashitang and Saili Medical also reported substantial trading volumes of 119,600 and 74,200 shares, with transaction values of around 208 million yuan and 185 million yuan respectively [1] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 188 million yuan from institutional investors and 252 million yuan from speculative funds, while retail investors saw a net inflow of 439 million yuan [2] - The capital flow data indicates varying investor sentiment, with retail investors showing a positive trend in the sector [2] Stock-Specific Capital Flow - Luyuan Pharmaceutical had a net inflow from retail investors of approximately 1.02 billion yuan, despite a net outflow from institutional and speculative investors [3] - Jiashitang and Saili Medical also experienced mixed capital flows, with Jiashitang seeing a net inflow of 84.96 million yuan from institutional investors [3]

证券代码：000028、200028 证券简称：国药一致、一致B 公告编号：2025-48 国药集团一致药业股份有限公司 2025年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1．本次股东会未出现否决议案的情形。 2．本次股东会不涉及变更以往股东会决议的情况。 一、 会议召开情况 1．召开时间： （1）现场会议时间：2025年12月31日（星期三）9:30； （2）网络投票时间：2025年12月31日；其中，通过深圳证券交易所交易系 统进行投票的时间为2025年12月31日9:15-9:25，9:30-11:30和13:00-15:00；通过 深圳证券交易所互联网投票系统投票时间为2025年12月31日9:15-15:00期间的任 意时间。 参加本次股东会的股东及股东代理人 253 人、代表股份 327,069,591 股、占 本公司有表决权总股份 58.7657%。其中，A 股股东及股东代理人 216 人、代表 股份 319,931,494 股，占本公司 A 股股东有表决权股份总数 65.9362%；B 股股 东及股 ...

京天股字（2025）第 808 号 致：国药集团一致药业股份有限公司 国药集团一致药业股份有限公司（以下简称"公司"）2025 年第三次临时股东 会（以下简称"本次股东会"）采取现场投票与网络投票相结合的方式，现场会议于 2025 年 12 月 31 日在深圳市福田区八卦四路 15 号一致药业大厦 5 楼会议室召开。 北京市天元（深圳）律师事务所（以下简称"本所"）接受公司聘任，指派本所律师 通过现场方式对本次股东会进行见证，并根据《中华人民共和国公司法》（以下简 称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上 市公司股东会规则》（以下简称"《股东会规则》"）以及《国药集团一致药业股份 有限公司章程》（以下简称"《公司章程》"）等有关规定，就本次股东会的召集、 召开程序、出席现场会议人员的资格、召集人资格、会议表决程序及表决结果等事 项出具本法律意见。 为出具本法律意见，本所律师审查了《国药集团一致药业股份有限公司第十届 董事会 2025 年第九次临时会议决议公告》《国药集团一致药业股份有限公司关于 召开 2025 年第三次临时股东会的通知》（以下简称"《股东会通知》"）以及本所 ...

Group 1 - The Ningxia Drug Administration conducted inspections on 31 pharmaceutical wholesale and retail companies, including notable firms like Lao Bai Xing, Hai Wang Bio, and Guo Yao Yi Zhi, focusing on organizational structure, quality management, computer systems, facilities, and drug procurement and sales [1][3] - The inspections revealed that Ningxia Tong Sheng Xiang Tong Ji Tang Pharmaceutical Co., Ltd. had 5 major defects and 5 general defects during its routine check from April 20 to 22, 2020, and was ordered to rectify these issues [1] - Ningxia Hai Wang Pharmaceutical Co., Ltd. was found to have 3 major defects and 1 general defect during its inspection on June 1 to 2, 2020, and was also instructed to make corrections [1] Group 2 - Ningxia Guo Da Pharmacy Chain Co., Ltd. had 1 major defect and 2 general defects during its inspection on June 15 to 16, 2020, and was required to rectify the issues [2] - Ningxia Tong Sheng Xiang Tong Ji Tang Pharmaceutical Co., Ltd. was established on June 29, 2017, with a registered capital of 23.8 million RMB, and is primarily owned by Lanzhou Hui Ren Tang Pharmaceutical Chain Co., Ltd., which holds a 92% stake [3] - Lao Bai Xing Pharmacy, a significant player in the retail pharmaceutical sector, was founded on December 1, 2005, with a registered capital of 292 million RMB, and is listed on the Shanghai Stock Exchange since April 23, 2015 [3] Group 3 - Ningxia Hai Wang Pharmaceutical Co., Ltd. was founded on March 15, 2002, with a registered capital of 10 million RMB, and is primarily owned by Henan Hai Wang Pharmaceutical Group Co., Ltd., which holds a 70% stake [4] - Shenzhen Hai Wang Bioengineering Co., Ltd., established on December 13, 1992, has a registered capital of 2.763 billion RMB and was listed on the Shenzhen Stock Exchange on December 18, 1998 [4] - The Hai Wang Group, founded in 1989, focuses on the pharmaceutical and health industry, with a sales scale of approximately 77.4 billion RMB in 2019 and a brand value of 91.568 billion RMB in 2020 [4] Group 4 - Ningxia Guo Da Pharmacy Chain Co., Ltd. was established on November 17, 2008, with a registered capital of 70 million RMB, and is primarily owned by Guo Yao Holding Guo Da Pharmacy Co., Ltd., which holds a 70% stake [5] - Guo Yao Yi Zhi, the parent company of Guo Da Pharmacy, is a comprehensive pharmaceutical listed company under China National Pharmaceutical Group, holding a 60% stake in Guo Yao Holding [5][6] - Guo Yao Yi Zhi was founded on August 2, 1986, with a registered capital of 428 million RMB, and was listed on the Shenzhen Stock Exchange on August 9, 1993 [6]

Group 1 - The chairman of Shandong Pharmaceutical Glass Co., Ltd., He Yonggang, has resigned, marking a significant personnel change shortly after the company was indirectly controlled by China National Pharmaceutical Group (Sinopharm) [1][19] - He Yonggang, aged 61, has had a long career with Shandong Pharmaceutical Glass, holding various key positions, and his resignation is attributed to age despite his term being set until May 2028 [2][20] - Zhang Jun, the current general manager, has been appointed to take over the chairman's responsibilities, bringing extensive production management and R&D experience to the role [2][20] Group 2 - Shandong Pharmaceutical Glass, established in 1970 and listed in 2002, specializes in the production of pharmaceutical glass packaging, covering a complete pharmaceutical packaging industry chain [4][22] - In June, Sinopharm and its Hong Kong subsidiary invested 2.449 billion yuan in Shandong Pharmaceutical Glass, acquiring a 51% stake in its controlling shareholder, thus indirectly controlling 19.5% of the company [4][22] - The company has achieved a nearly 90% market share in the domestic borosilicate molded bottle sector, which has been historically dominated by international giants [5][22] Group 3 - In 2024, Shandong Pharmaceutical Glass reported revenues of 5.125 billion yuan, a year-on-year increase of 287 million yuan, and a net profit of 904 million yuan, up 21.86% [5][22] - However, in the first three quarters of 2025, the company experienced a revenue decline of 11.1% to 3.4 billion yuan and a net profit drop of 24.7% to 543 million yuan, attributed to product homogenization and weak downstream demand [5][23] - The overall pharmaceutical distribution industry in China is experiencing a slowdown, prompting a trend towards consolidation among major players [14][30] Group 4 - Sinopharm is undergoing significant personnel changes across its pharmaceutical distribution companies, reflecting potential strategic shifts within the organization [6][13] - Recent leadership changes include the resignation of several key executives, indicating a response to the challenges faced by the company, including declining revenue growth [6][29] - Sinopharm is focusing on expanding its market presence by enhancing core customer relationships and increasing the share of high-value products in its overall revenue [31]

证券日报网讯 12月15日晚间，国药一致发布公告称，公司第十届董事会2025年第九次临时会议审议通 过《关于其他应收款坏账损失核销的议案》《关于召开2025年第三次临时股东会的议案》。 （文章来源：证券日报） ...